| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Nirianne Marie Q Palacpac | Q60390503 |
| P2093 | author name string | Toshihiro Horii | |
| P2860 | cites work | Viral vectors as vaccine platforms: from immunogenicity to impact | Q24574798 |
| Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics | Q27973871 | ||
| Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution | Q28529647 | ||
| Human infections and detection of Plasmodium knowlesi | Q28709120 | ||
| A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen | Q30152118 | ||
| Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences. | Q30363119 | ||
| Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial | Q30991737 | ||
| Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines | Q33812439 | ||
| Fast vaccine design and development based on correlates of protection (COPs). | Q34291098 | ||
| Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study | Q34530710 | ||
| The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection | Q34684347 | ||
| Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. | Q34749432 | ||
| Defining the geographical range of the Plasmodium knowlesi reservoir | Q35133805 | ||
| How sex and age affect immune responses, susceptibility to infections, and response to vaccination | Q35527150 | ||
| Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites | Q35560599 | ||
| P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections | Q35561160 | ||
| Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial | Q36167716 | ||
| High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine | Q36264198 | ||
| Large screen approaches to identify novel malaria vaccine candidates | Q36510147 | ||
| Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children | Q37130595 | ||
| Vaccines: correlates of vaccine-induced immunity | Q37193062 | ||
| Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda. | Q37310848 | ||
| Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses | Q37402846 | ||
| Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda | Q37576425 | ||
| Serum bactericidal antibody assays - The role of complement in infection and immunity | Q38549601 | ||
| Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine | Q91286777 | ||
| Comprehensive analysis of antibody responses to Plasmodium falciparum erythrocyte membrane protein 1 domains | Q91820560 | ||
| Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial | Q91837993 | ||
| Malaria vaccination and rebound malaria | Q91838000 | ||
| Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some Plasmodium falciparum strains | Q91996104 | ||
| Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines | Q92071485 | ||
| An overview of VaxchoraTM, a live attenuated oral cholera vaccine | Q92146366 | ||
| Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP | Q92325722 | ||
| Persistent transmission of Plasmodium malariae and Plasmodium ovale species in an area of declining Plasmodium falciparum transmission in eastern Tanzania | Q92342917 | ||
| Antimalarial drug resistance in Africa: the calm before the storm? | Q92375746 | ||
| Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential | Q92501761 | ||
| RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: A case-control study | Q92599701 | ||
| Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study | Q92957962 | ||
| Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000-17: a spatial and temporal modelling study | Q92957966 | ||
| Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants | Q93148172 | ||
| The GMZ2 malaria vaccine: from concept to efficacy in humans. | Q38658724 | ||
| Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers. | Q38714971 | ||
| Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection | Q38949224 | ||
| Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa | Q39015634 | ||
| Long-term effectiveness of plasma-derived hepatitis B vaccine 22-28 years after immunization in a hepatitis B virus endemic rural area: is an adult booster dose needed? | Q39033664 | ||
| Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective | Q39255393 | ||
| Sterile protection against human malaria by chemoattenuated PfSPZ vaccine | Q39267443 | ||
| Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial | Q40042826 | ||
| Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis | Q40096524 | ||
| Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display | Q40173704 | ||
| Systems analysis of protective immune responses to RTS,S malaria vaccination in humans | Q40334346 | ||
| Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships | Q41620472 | ||
| Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis | Q41992385 | ||
| Adjuvant system AS01: helping to overcome the challenges of modern vaccines | Q42051427 | ||
| Vaxchora: The First FDA-Approved Cholera Vaccination in the United States | Q42726710 | ||
| RTS,S Malaria Vaccine and Increased Mortality in Girls | Q42848608 | ||
| Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men. | Q43923962 | ||
| Controlled Human Malaria Infection: Applications, Advances and Challenges. | Q44168331 | ||
| Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine | Q44168441 | ||
| Evaluating anti-disease immunity to malaria and implications for vaccine design. | Q46222698 | ||
| Vaccine Prevention of Meningococcal Disease in Africa: Major Advances, Remaining Challenges | Q46535546 | ||
| Synergistic malaria vaccine combinations identified by systematic antigen screening | Q46748512 | ||
| Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial | Q46796163 | ||
| Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein | Q47161602 | ||
| Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection | Q47372765 | ||
| A controlled human malaria infection model enabling evaluation of transmission-blocking interventions | Q47547431 | ||
| Sex and Gender Differences in the Outcomes of Vaccination over the Life Course | Q47662452 | ||
| Interpreting challenge data from early phase malaria blood stage vaccine trials | Q48023890 | ||
| Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem | Q50207341 | ||
| Malaria Vaccines: Recent Advances and New Horizons | Q56362064 | ||
| Controlled Human Malaria Infection with Graded Numbers of NF135.C10- or NF166.C8-Infected Mosquitoes | Q56362793 | ||
| Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development | Q58699135 | ||
| Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants | Q59151600 | ||
| Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Infections | Q61447733 | ||
| A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine | Q63634603 | ||
| Environmental risk factors and exposure to the zoonotic malaria parasite Plasmodium knowlesi across northern Sabah, Malaysia: a population-based cross-sectional survey | Q64095858 | ||
| Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa | Q64125345 | ||
| Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose | Q64132166 | ||
| Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody | Q65937995 | ||
| Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity | Q90560580 | ||
| Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2 | Q90609797 | ||
| The changing landscape of Plasmodium falciparum drug resistance in the Democratic Republic of Congo | Q90879620 | ||
| First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria | Q90980923 | ||
| Prospects for Malaria Vaccines: Pre-Erythrocytic Stages, Blood Stages, and Transmission-Blocking Stages | Q91114683 | ||
| Tolerance May Be More Appropriate Than Immunity When Describing Chronic Malaria Infections | Q91191362 | ||
| Whole parasite vaccines for the asexual blood stages of Plasmodium | Q91221222 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | malaria vaccine | Q6741353 |
| P577 | publication date | 2020-04-27 | |
| P1433 | published in | F1000Research | Q27701587 |
| P1476 | title | Malaria vaccines: facing unknowns | |
| P478 | volume | 9 |
Search more.